Birgit Engesæter

Quality assurance of human papillomavirus (HPV) testing in the implementation of HPV primary screening in Norway: an inter-laboratory reproducibility study

P. Castle, O. Vintermyr, M. Nygård, 2016, BMC Infectious Diseases.

Impact of scheduled appointments on cervical screening participation in Norway: a randomised intervention

S. Lönnberg, K. Johansson, A. Tropé, 2016, BMJ Open.

CervicalScreen Norway – A screening programme in transition

T. Bjørge, A. Tropé, G. Skare, 2022, Norsk Epidemiologi.

A Gene Signature Identifying CIN3 Regression and Cervical Cancer Survival

E. Janssen, I. Haldorsen, E. Hoivik, 2021, Cancers.

High-Grade Cervical Intraepithelial Neoplasia (CIN) Associates with Increased Proliferation and Attenuated Immune Signaling

Beatrix Bicskei, E. Janssen, M. K. Halle, 2021, International journal of molecular sciences.

Real-world data on cervical cancer risk stratification by cytology and HPV genotype to inform the management of HPV-positive women in routine cervical screening

T. Bjørge, P. Castle, M. Nygård, 2020, British Journal of Cancer.

The legal framework for European cervical cancer screening programmes

S. Lönnberg, A. Anttila, M. Arbyn, 2018, European journal of public health.

Randomized Implementation of a Primary Human Papillomavirus Testing–based Cervical Cancer Screening Protocol for Women 34 to 69 Years in Norway

P. Castle, O. Vintermyr, M. Nygård, 2022, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.